Kyverna Therapeutics (KYTX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with a lead product candidate, KYV-101, targeting over 15 indications in neuroinflammation and rheumatology.

• KYV-101 is an autologous, fully human CD19 CAR T-cell therapy, licensed from the NIH, designed for deep B cell depletion and durable remission.

• Pipeline includes next-generation CAR T-cell therapies (autologous and allogeneic), with KYV-102 using a proprietary rapid manufacturing process.

• No products approved for sale; relies on contract manufacturing organizations for production and is developing its own manufacturing process (Ingenui-T).

• Lacks commercial infrastructure; expects significant commercialization expenses if regulatory approval is obtained.

Financial performance and metrics

• No revenue from product sales since inception in June 2018; all resources devoted to R&D, manufacturing, personnel, technology, and capital raising.

• As of December 31, 2024, 43,214,918 shares of common stock outstanding; net tangible book value per share was $6.17.

• After a $50 million offering at $2.30 per share, as adjusted net tangible book value would be $4.85 per share.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, capital expenditures, working capital, and administrative expenses.

• May use a portion for in-licensing, acquisitions, or investments in complementary businesses or technologies, though no current agreements exist.

• Retains broad discretion over use of proceeds; timing and allocation depend on business needs and market conditions.